- Min.Order :1 Gram
- Purity: 99.0%
- Payment Terms : L/C,D/A,D/P,T/T,Other
Keywords
Telmisartan 144701-48-4 C33H30N4O2
Quick Details
- Appearance:Solid
- Application:Organic synthesis
- PackAge:IN 25kg drums
- ProductionCapacity:10|Metric Ton|Month
- Storage:In Room Temperature
- Transportation:As per MSDS
Superiority:
Henan Newblue Chemical Co., Ltd. is located in Zhengzhou High-tech Development Zone with import and export license.
We passed ISO 9001:2008 in 2009, and won "High-tech Enterprise" by provincial government in 2013.The objective of the company is to put quality first and put our customer’s needs first - the satisfaction of our customers is the company's ultimate goal.
Improving product quality and service level is our responsibility, and creating more value for our customer’s is our purpose. We are constantly striving to make Henan Newblue a leading chemical supplier, and hope to create a better future with you.
Details:
Telmisartan Basic information
Chemical Properties Mechanisms of Action Side Effects Patent
Product Name: Telmisartan
Synonyms: TU-199;TELMISARTAN;PRITOR;MICARDIS;BIBR 277;4'[(1,4'-DIMETHYL-2'-PROPYL[2,6'-BI-1H-BENZIMIDAZOL]-1'-YL)METHYL][1,1'-BIPHENYL]-2-CARBOXYLIC ACID;4'-[(1,4'-DIMETHYL-2'-PROPYL[2,6'-BI-H-BENZIMIDAZOL]-1'-YL)METHYL][1,1'-BIPHENYL]-2-CARBOXYLIC ACID;3-methoxy-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl sulfinyl]-2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraene
CAS: 144701-48-4
MF: C33H30N4O2
MW: 514.63
EINECS:
Product Categories: Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;INTERMEDIATESOF;Antihypertensive;Imidazoles;(intermediates of telmisartan);Telmisartan;Hypertension;Intermediates & Fine Chemicals;Pharmaceuticals;API's;Other Products;Hypertension.;CARADRIN
Mol File: 144701-48-4.mol
Telmisartan Structure
Telmisartan Chemical Properties
Melting point 261-263°C
density 1.16
RTECS DV2037500
storage temp. Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility DMSO: >5 mg/mL at 60 °C
form solid
color white
Water Solubility insoluble
Merck 14,9129
CAS DataBase Reference 144701-48-4(CAS DataBase Reference)
Safety Information
Hazard Codes Xi
Risk Statements 36/37/38
Safety Statements 22-24/25-36-26
WGK Germany 2
Hazardous Substances Data 144701-48-4(Hazardous Substances Data)
MSDS Information
Provider Language
4'-[[1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl]-methyl]-1,1'-biphenyl-2-carboxylic acid 1,1-dimethylethyl ester English
SigmaAldrich English
Telmisartan Usage And Synthesis
Chemical Properties White or off-white crystalline powder, odorless and tasteless. Soluble in chloroform, slightly soluble in methanol, very slightly soluble in acetone, practically insoluble in water. Slightly soluble in 0.1mol/L hydrochloric acid, soluble in 0.1mol/L sodium hydroxide.
Absorption coefficient（E1％1cm）：509～541
Mechanisms of Action 80mg of telmisartan for the human body will practically completely counter the high blood pressure caused by angiotension II. Effects will last for 24 and can still be detected within 48 hours. Blood pressure-lowering effects should gradually become apparent within 3 hours after the initial dose. If treatment is suddenly interrupted, blood pressure will return to the same level as before treatment in a matter of days, and there will be no rebound high blood pressure. In a clinical trial that compared two kinds of antihypertensive drugs, patients in the treatment group experienced lower rates of coughing than those in the group treated by angiotensin converting enzyme inhibitors.
Telmisartan has a half-life of 18～24 hours, and will take effect 1～4 hours after taken. Medicinal effects can last for as long as 35 hours, with a high (T/P) ratio and outstanding effects in controlling morning blood pressure. Thus, this medicine can effectively control blood pressure for 24 hours, and it meets the once-daily medicinal standard (40～80mg, qd).
Clinical effects and characteristics:
Pharmacokinetics show: Rapid effects (0.3h), long duration (35.4h), little effect on heart rate when lowering blood pressure.
Compared to Enalapril: Stronger antihypertensive effects than Enalapril; when both are used in combination with diuretics, Telmisartan still appears to be superior and results in a lower coughing rate.
Compared to Lisinopril: More apparent antihypertensive effects (for both systolic and diastolic blood pressure), coughing rate for Telmisartan (16%) is drastically lower than that of Lisinopril (60%).
Compared to Atenolol: Similar antihypertensive effects, lower rate of side effects (impotence and fatigue).
Compared to Amlodipine: The Telmisartan group experienced noticeably lower heart rates four hours after ingestion and from six a.m. to twelve p.m.
Overall, Telmisartan has the following characteristics in comparison with other antihypertensive medicine: specific receptor effects, noticeable hypertensive effects, good diuretic effects, improvement of myocardial stenosis, safe usage, good tolerance, and convenient daily dosage.
Side Effects In the placebo control experiment, the incidence rate of negative events for the Telmisartan group (41.4%) was similar to that of the placebo group (43.9%). Negative events were unrelated to dosage, sex, age, or race.
The following lists negative reactions were accumulated via the 5788 hypertensive patients that were treated with Telmisartan in the clinical trial.
Negative effects are categorized by incident rate as:
Very common (>1/10); common (>1/100, <1/10=); uncommon (>1/1000, <1/100=); rare (>1/10000, <1/1000=); very rare (<1/100000=)
Bodily reaction: Common: Back pain (e.g. sciatica), chest pain, flu-like symptoms, infection symptoms (e.g. urinary tract infection including cystitis). Uncommon: sight abnormality, sweating.
Central and peripheral nervous system: Common: vertigo.
Digestive system: Common: stomach pain, diarrhea, indigestion, gastrointestinal disorders. Rare: dry mouth, bloating.
Muscle skeletal system: Common: joint pain, leg cramps or leg pain, muscle pain. Rare: Tenosensitis symptoms.
Nervous system: Rare: anxiety.
Respiratory system: Common: upper respiratory tract infection, including pharyngitis and rhinitis.
Skin and accessory system: Common: Skin abnormalities such as eczema.
Additionally, since Telmisartan entered the market, there have been individual cases of erythema, itching, syncope, insomnia, depression, stomach discomfort, vomiting, hypotension, bradycardia, tachycardia, dyspnea, eosinophilia, thrombocytopenia, weakness, and reduced work efficiency. Similar to other angiotensin II receptor blockers, very few cases have reported vascular edema, nettles, and other negative reactions.
The laboratory found: compared to the placebo, the Telmisartan group occasionally exhibited lowered hemoglobin or raised uric acid. Any increase in serum creatinine or liver enzymes in the Telmisartan group was similar or lower than that of the placebo group.
Patent Telmisartan was originally formulated by the German pharmaceutical company Boehringer Ingelheim; it earned the German patent EP502,314 in 1991, was first approved to enter the American market in November 1998, and then entered German, Philippines, Australian, Belgium, British, and other markets.
Chemical Properties White or off white crystalline powder
Uses cardiotonic
Uses Telmisartan is an angiotensin II receptor antagonist.
Uses anti-cancer agent
Uses Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart
Definition ChEBI: A member of the class of benzimidazoles used widely in the treatment of hypertension.
Telmisartan Preparation Products And Raw materials
Raw materials N-Methyl-1,2-benzenediamine dihydrochloride
You Might Also Like
-
High Grade4-Fluoro-1,3-dioxolan-2-one 114435-02-8 Fast Delivery
CAS NO:114435-02-8
-
N-LAURYLDIETHANOLAMINE 1541-67-9
CAS NO:1541-67-9
-
423-55-2 PERFLUOROOCTYL BROMIDE
CAS NO:423-55-2
-
PENTAMETHYLDISILOXANE 1438-82-0
CAS NO:1438-82-0
-
124-41-4 CH3NaO Sodium methanolate
CAS NO:124-41-4
-
409071-16-5 C2BF2LiO4 Lithium difluoro(oxalato)borate(1-)
CAS NO:409071-16-5
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View